New Australian biosimilar guidance takes up WHO naming proposal
This article was originally published in Scrip
Executive Summary
Generic companies planning to market biosimilar medicines in Australia will have to apply to the World Health Organization for a unique INN identifying code, and all biosimilars will have to have a clearly distinguishable trade name, according to guidance just published by the Therapeutic Goods Administration (TGA).